ASX aspirant ReNerve, which this week launched an investor roadshow to market its initial public offering, is hoping to mirror the success of the only other life-sciences stock on the local bourse.
The nerve-repair company plans to list in late November on the back of an approved product in the United States market. Lead manager Alpine Capital is seeking to raise as much as $7 million for an enterprise value of $20.3 million, according to a prospectus lodged with the corporate regulator.has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: